Is AMLX a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on From LUCIDITY data to an FDA filing, with product revenue at None (Relyvrio withdrawn in 2024; consensus ~$28M for 2027). The bear case rests on the concentration risk remains the dominant one: avexitide now carries nearly all of the equity value, and a positive 78-patient trial still leaves FDA review risk, label risk, and the possibility of requests for more data. Analysts covering it are spread from $20.00 to $57.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The concentration risk remains the dominant one: avexitide now carries nearly all of the equity value, and a positive 78-patient trial still leaves FDA review risk, label risk, and the possibility of requests for more data. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $20.00, -27.8% from the $27.70 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

From LUCIDITY data to an FDA filing. The 78-participant registrational trial met its primary endpoint with a 55% reduction in Level 2 and Level 3 hypoglycemic events and hit its key secondary measures. The most optimistic analyst target on AMLX is $57.00, +105.8% from the $27.70 price. That figure is only reachable if this thesis works close to its best case.

The concentration risk remains the dominant one: avexitide now carries nearly all of the equity value, and a positive 78-patient trial still leaves FDA review risk, label risk, and the possibility of requests for more data. Amylyx has already failed a confirmatory Phase 3 once, with Relyvrio withdrawn from the market in 2024, so execution credibility is still being rebuilt. Launching a drug for a rare condition is costly, and adoption depends on endocrinologists and payers treating the effect size as a clear improvement over cheap off-label options. The company generates no product revenue and lost about $152 million over the trailing twelve months, so any delay pushes it toward a financing that would dilute existing holders. The stock is volatile: it more than tripled from its 52-week low of $10.83 to $41.14 and then fell about 18% in the month to October 16, 2026, and an insider sold about $831,000 of shares in early October. There is also a legacy legal item: a securities class action tied to 2022 to 2023 Relyvrio launch statements was settled for $6.5 million, with preliminary court approval in May 2026 and a final approval hearing scheduled for September 2026. The most pessimistic published target is $20.00, -27.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Clinical-stage biotech whose lead asset avexitide targets post-bariatric hypoglycemia, with a Phase 3 readout as the near-term swing factor.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (From LUCIDITY data to an FDA filing) stalling in the reported numbers rather than in the narrative, the risk above (the concentration risk remains the dominant one: avexitide now carries nearly all of the equity value, and a positive 78-patient trial still leaves FDA review risk, label risk, and the possibility of requests for more data) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Amylyx is a clinical-stage biotech developing drugs for conditions with few approved options. Its lead candidate, avexitide, succeeded in Phase 3 for post-bariatric hypoglycemia and is headed for an FDA filing, and it also runs programs in Wolfram syndrome (AMX0035), ALS (AMX0114) and a preclinical asset (AMX0318). It sells no products today.

Not meaningfully. Its only approved product, Relyvrio for ALS, was withdrawn from the market in 2024 after the confirmatory PHOENIX Phase 3 trial failed to show benefit. Since then Amylyx has operated as a pre-revenue clinical-stage company funded entirely by its balance sheet. Analysts on average expect about $28 million of revenue in 2027 if avexitide is approved and launched.

Avexitide is a GLP-1 receptor antagonist for post-bariatric hypoglycemia, a condition where gastric bypass patients suffer severe blood-sugar crashes. There is no FDA-approved treatment for it. Because avexitide is the only late-stage asset in the portfolio, and now has positive Phase 3 data, its filing, review and launch carry most of the company's value.